Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
Tenaya Therapeutics, Inc. (TNYA) to participate in TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. The company aims to develop therapies for heart disease.
02/27/2024 - 04:30 PM
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in TD Cowen’s 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Details of participation are as follows:
TD Cowen 44th Annual Health Conference Format: Genetic Medicines Panel Date: Tuesday, March 5 Time: 2:10 PM ET – 3:10 PM ET
Leerink Partners Global Biopharma Conference 2024 Format: Fireside Chat Date: Tuesday, March 12 Time: 10:40 AM ET – 11:10 AM ET
The live presentations will be webcast and may be accessed from the Investors section of Tenaya’s website . A replay of the webcasts will be available on the Tenaya website for approximately 30 days following each conference.
About Tenaya Therapeutics Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Leveraging its integrated and interrelated Gene Therapy, Cellular Regeneration and Precision Medicine platforms and proprietary core capabilities, the company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. Tenaya’s most advanced candidates include TN-201, a gene therapy for MYBPC3 -associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2 -associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor being initially developed for heart failure with preserved ejection fraction (HFpEF). Tenaya also has multiple early-stage programs progressing through preclinical development. For more information, visit www.tenayatherapeutics.com .
When will Tenaya Therapeutics participate in TD Cowen's 44th Annual Health Care Conference?
Tenaya Therapeutics will participate in TD Cowen's 44th Annual Health Care Conference on Tuesday, March 5 from 2:10 PM ET to 3:10 PM ET.
What is the format of Tenaya Therapeutics' participation in Leerink Partners Global Biopharma Conference 2024?
Tenaya Therapeutics will participate in Leerink Partners Global Biopharma Conference 2024 in a Fireside Chat format on Tuesday, March 12 from 10:40 AM ET to 11:10 AM ET.
Where can the live presentations of Tenaya Therapeutics be accessed?
The live presentations of Tenaya Therapeutics can be accessed from the Investors section of the company's website.
Will there be a replay of the webcasts available?
Yes, a replay of the webcasts will be available on the Tenaya website for approximately 30 days following each conference.
TNYA Rankings
#4071 Ranked by Stock Gains
TNYA Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About TNYA
tenaya therapeutics is a privately-held biopharmaceutical company backed by the column group. the company was founded in 2016 by world-leading scientists from the gladstone institute’s cardiovascular division and the university of texas southwestern medical center. tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration. tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.